Aurora Blucher
Overview
Explore the profile of Aurora Blucher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
898
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuhn M, Zhang Y, Favate J, Morita M, Blucher A, Das S, et al.
Am J Physiol Gastrointest Liver Physiol
. 2022 Oct;
323(6):G571-G585.
PMID: 36194131
Colorectal cancer (CRC) is a leading cause of cancer-related death. There is an urgent need for new methods of early CRC detection and monitoring to improve patient outcomes. Extracellular vesicles...
2.
Bottomly D, Long N, Schultz A, Kurtz S, Tognon C, Johnson K, et al.
Cancer Cell
. 2022 Jul;
40(8):850-864.e9.
PMID: 35868306
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and clinical annotations for a large...
3.
Johnson B, Creason A, Stommel J, Keck J, Parmar S, Betts C, et al.
Cell Rep Med
. 2022 Mar;
3(2):100525.
PMID: 35243422
Mechanisms of therapeutic resistance and vulnerability evolve in metastatic cancers as tumor cells and extrinsic microenvironmental influences change during treatment. To support the development of methods for identifying these mechanisms...
4.
Labrie M, Li A, Creason A, Betts C, Keck J, Johnson B, et al.
NPJ Precis Oncol
. 2021 Oct;
5(1):92.
PMID: 34667258
In a pilot study, we evaluated the feasibility of real-time deep analysis of serial tumor samples from triple negative breast cancer patients to identify mechanisms of resistance and treatment opportunities...
5.
Westin S, Labrie M, Litton J, Blucher A, Fang Y, Vellano C, et al.
Clin Cancer Res
. 2021 Sep;
27(23):6354-6365.
PMID: 34518313
Purpose: On the basis of strong preclinical rationale, we sought to confirm recommended phase II dose (RP2D) for olaparib, a PARP inhibitor, combined with the AKT inhibitor capivasertib and assess...
6.
Chamberlin S, Blucher A, Wu G, Shinto L, Choonoo G, Kulesz-Martin M, et al.
Front Pharmacol
. 2019 Jun;
10:557.
PMID: 31214023
A body of research demonstrates examples of and synergy between natural products and anti-neoplastic drugs for some cancers. However, the underlying biological mechanisms are still elusive. To better understand biological...
7.
Tyner J, Tognon C, Bottomly D, Wilmot B, Kurtz S, Savage S, et al.
Nature
. 2018 Oct;
562(7728):526-531.
PMID: 30333627
The implementation of targeted therapies for acute myeloid leukaemia (AML) has been challenging because of the complex mutational patterns within and across patients as well as a dearth of pharmacologic...